Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications

J Clin Oncol. 2020 Apr 20;38(12):1367-1368. doi: 10.1200/JCO.19.02972. Epub 2020 Mar 11.

Authors

Noa Biran¹, David H Vesole¹, Michele L Donato¹, Andrew Ip¹, Gurbakhash Kaur¹, Stuart Goldberg¹, David S Siegel¹

Affiliation

¹ Noa Biran, MD; David H. Vesole, MD, PhD; Michele L. Donato, MD; Andrew Ip, MD; Gurbakhash Kaur, MD; Stuart Goldberg, MD; and David S. Siegel, MD, PhD; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.

PMID: 32160077
DOI: 10.1200/JCO.19.02972

No abstract available

Publication types

Letter
Comment

MeSH terms

Biological Products*
Disease Progression
Humans
Lenalidomide
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy
Smoldering Multiple Myeloma*

Substances

Biological Products
Lenalidomide